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Introduction {#s1}
============

Epigenetics refers to a group of heterogeneous, but interrelated processes that regulate transcription without changing the DNA nucleotide sequence. Specifically, epigenetics involves methylation at the 5′ position of cytosine bases in CpG dinucleotide pairs, covalent modifications of histones, or the activities of non-coding RNA species [@pone.0109896-Bird1]. Although the DNA methylation of some gene promoters, for example those involved in cell differentiation or imprinting, is induced in early life and persists throughout the life course, other DNA methylation marks appear to be more plastic [@pone.0109896-Goldberg1], particularly during periods of rapid growth [@pone.0109896-Szyf1]. Altered epigenetic regulation by DNA methylation of specific genes has been implicated as a causal factor in a number of non-communicable diseases [@pone.0109896-Burdge1], [@pone.0109896-Burdge2]. Genes that retain epigenetic plasticity may respond to environmental inputs, including nutrition, and so may alter gene and cell function. Thus understanding the impact of nutrient intakes on the epigenome has important implications for dietary choices in relation to health.

Dietary fat intake can modify capacity for polyunsaturated fatty acid (PUFA) by changing the mRNA expression of Δ6 (D6d) and Δ5 (D5d) desaturases [@pone.0109896-Cho1], [@pone.0109896-Cho2]. Although product inhibition is likely to be involved, the underlying mechanism has not been well-described. Changes in dietary fatty acid intake can alter the activity of the PUFA biosynthesis pathway in rodent models via changes in the epigenetic regulation of key genes. Increasing dietary α-linolenic acid content during pregnancy and lactation in mice increased the average methylation of the fatty acid desaturase (Fads)-2, which encodes D6d, promoter and of intron 1 by up to 2% in the liver of dams [@pone.0109896-Niculescu1], [@pone.0109896-Niculescu2]. Feeding pregnant rats diets containing different amounts of saturated or n-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) induced hypermethylation of specific CpG loci in the Fads2 promoter and decreased mRNA expression in the liver of the adult offspring. This was accompanied by decreased proportions of docosahexaenoic acid (DHA) and arachidonic acid in membrane and plasma phospholipids [@pone.0109896-Hoile1]. Feeding adult female rats a fish oil-enriched diet for 9 weeks also induced lower Fads2 mRNA expression and increased methylation of specific CpG loci in the Fads2 promoter [@pone.0109896-Hoile1]. These changes were reversed when the animals were switched to a soybean oil-base diet [@pone.0109896-Hoile1]. Feeding dams either 7% and 21% (w/w) safflower oil, hydrogenated soybean oil, butter or fish oil induced increased methylation of specific CpG loci in the Fads2 promoter and decreased its expression in aortae in the adult offspring [@pone.0109896-Kelsall1]. Mutation of one CpG locus that was hypermethylated in both the liver and aortae of these offspring, which is located within an estrogen receptor response element, decreased the activity of the Fads2 promoter [@pone.0109896-Kelsall1]. This indicates that at least some of the hypermethylated loci were involved directly in the regulation of Fads2 transcription. Together, these findings support the suggestion that variation in the fatty acid supply during development can induce persistent changes in the epigenetic regulation of LCPUFA biosynthesis.

To our knowledge, no study has examined the effects of dietary fatty acid intake on the epigenetic regulation of genes involved in PUFA metabolism in adult humans. In this study, we tested the hypothesis that dietary supplementation with preparations containing either predominately n-9 monounsaturated fatty acids (olive oil; OO) or n-3 LCPUFA induces differential changes in the DNA methylation of genes involved in LCPUFA biosynthesis. We measured methylation status of individual CpG loci in the 5′ regulatory region of FADS2, FADS1 (which encodes D5d) and elongase (ELOVL)-5 and ELOVL2 (which encode elongase 5 and elongase 2, respectively) in DNA extracted from peripheral blood mononuclear cells (PBMCs) isolated from patients with chronic renal disease. We also tested whether any induced changes in DNA methylation were related to the level of mRNA and whether any effects of n-3 LCPUFA on the DNA methylation of genes involved in LCPUFA biosynthesis could be replicated in blood from healthy adults.

Subjects and Methods {#s2}
====================

Ethical statement {#s2a}
-----------------

The studies were conducted according to the principles expressed in the Declaration of Helsinki. Study 1 was approved by the Royal Perth Hospital Ethics Committee (EC2004/045) and is registered on the Australian Clinical Trials Register (ACTRN012605555588640). Subjects gave informed, written consent. Study 2 received ethical approval from the National Research Ethics Service Committee, South Central -- Berkshire (REC reference number 11/SC/0384). Participants provided informed, written consent.

Dietary intervention trials and sample collection {#s2b}
-------------------------------------------------

The samples used in this study were derived from specimens collected in two dietary intervention studies, one in patients with chronic kidney disease at the University of Western Australia (Perth, Australia) (Study 1) and the other in healthy adults at the University of Southampton (Southampton, UK) (Study 2).

The design of the dietary intervention trial in Study 1 has been described in detail elsewhere [@pone.0109896-Mori1]. The samples used in the current study were from a sub-group of 29 men and women for whom paired before and end of intervention samples were available, who were non-smokers and non-diabetic, with moderate to severe chronic renal impairment (estimated glomerular filtration rate between 15 and 60 ml/min/1.73 m^2^ (normal range≥90 ml/min/1.73 m^2^) and serum creatinine less than 350 µmol/l (normal range 53 to 115 µmol/l). The primary exclusion criteria were use of non-steroidal anti-inflammatory or immunosuppressive medication, consumption of fish oil supplements, consumption of more than one portion of fish per week or consumption of more than 4 alcoholic drinks per day. Six out of the total cohort of 35 subjects only had single samples and so were excluded from the present analysis. The details of the subjects from whom samples were analysed in the current study are summarised in [Table 1](#pone-0109896-t001){ref-type="table"}.

10.1371/journal.pone.0109896.t001

###### Subject characteristics at baseline.

![](pone.0109896.t001){#pone-0109896-t001-1}

                                    Male           Female              
  ------------------------- -------------------- ---------- ---------- ----------
  n                                  8               8          6          7
  Age (years)                       55±4            61±3       53±6       55±4
  BMI (kg/m^2^)                   25.7±1.0        27.2±1.4   28.7±2.6   29.5±2.8
  eGRF (ml/min/1.73 m^2)^         37.6±4.0        34.9±2.4   36.5±4.0   32.7±3.9
  Cholesterol (mmol/l)            5.1±0.2         4.6±0.2    4.8±0.4    4.7±0.2
  Triglyceride (mmol/l)           2.4±0.3         1.7±0.2    1.1±0.1    1.8±0.5
  Creatinine (µmol/l)              209±22          192±16     151±15     163±17
  Glucose (mmol/l)                5.0±0.2         5.0±0.2    4.5±0.3    5.1±0.3
  HOMA-IR                         3.0±0.4         2.4±0.3    2.3±0.8    3.2±1.0
                             **Study 2 cohort**                        
  n                                  8               12                
  Age (years)                       23±1            30±4               
  BMI (kg/m^2^)                   22.6±0.5        21.5±0.5             

Values are mean ± SEM. n-3 LCPUFA, fish oil; OO, olive oil; BMI, body mass index; eGRF, estimated glomerular filtration rate; HOMA-IR, homeostatic model assessment of insulin resistance. Comparisons within male and female subjects by Student's unpaired t test showed no significant differences (P\>0.05) between treatment groups.

Subjects consumed 4 g n-3 LCPUFA, eicosapenatenoic acid (EPA; 1.8 g), dosocapentaenoic acid (DPA; 0.2 g) and DHA (1.5 g) ethyl esters in four 1 g capsules (Omacor, Solvay Pharmaceuticals, Pymble, NSW, Australia) or 4 g olive oil (OO) in four 1 g capsules (Cardinal Health Australia, Braeside, Victoria, Australia) each day for 8 weeks. The study had a randomised double blind design. Venous blood samples were collected in the fasting state and differential blood counts were determined as described [@pone.0109896-Mori1]. PBMCs were isolated as described [@pone.0109896-Mori2], stored at −80°C, transported for analysis on dry ice and stored at −80°C until analysed.

The subjects for comparator analyses in Study 2 were the health subjects in a reference group in a study that compared the effect of fish oil supplementation in individuals who were of normal BMI or clinically obese. Subjects men and women of BMI between 18.5 and 25 kg/m^2^, with fasting plasma glucose \<5 mmol/l, triacylglycerol \<1.0 mmol/l and total cholesterol less than 5 mmol/l who did not consume fish oil or other oil supplements, who did not eat more than one oily fish meal per week, did not have diagnosed diabetes or chronic gastrointestinal problems and were not pregnant or planning to become pregnant within the study period. Subjects were excluded if they used prescribed medicine to control inflammation, to control blood lipids or to control blood pressure. The characteristics of the subjects in Study 2 are detailed in [Table 1](#pone-0109896-t001){ref-type="table"}. A fasting venous blood sample was collected at baseline and an aliquot of whole blood was stored at −20°C. Subjects then received EPAX6000 TG (EPAX, Oslo, Norway) which provided 1.1 g EPA, 0.1 g DPA plus 0.8 g DHA in the form of a triacylglycerol per day for 12 weeks. A second fasting blood sample was collected at the end of the study and an aliquot of whole blood stored at −20°C.

Isolation of DNA and analysis of DNA methylation {#s2c}
------------------------------------------------

Genomic DNA was isolated from 200 µl PBMC or whole blood using the QIAmp DNA blood mini kit (Qiagen, 51106) according to the manufacturer's instructions. The level of methylation of individual CpG dinucleotides in the 5′ regulatory regions of FADS 1 and 2, and ELOVL 2 and 5 was measured from −504 to −1037, from −18 to −1661, from −292 to −508 and from −6 to −686 bases, respectively, upstream from the transcription start site ([Figure 1](#pone-0109896-g001){ref-type="fig"}) using sodium bisulphite pyrosequencing essentially as described [@pone.0109896-Hoile1]. PCR primers and pyrosequencing probes are listed in [Tables 2](#pone-0109896-t002){ref-type="table"} and [3](#pone-0109896-t003){ref-type="table"}. Bisulphite conversion was carried out using the EZ DNA methylation kit (ZymoResearch, D5006). Modified DNA was amplified using KAPA2G Robust Hot Start Taq DNA polymerase (Anachem, KK5702). PCR products were immobilised on streptavidin--sepharose beads (GE Healthcare UK Ltd., 17-5113-01), washed, denatured and released into annealing buffer containing the sequencing primers. Pyrosequencing was carried out using CDT reagents (Qiagen, 972824) on a PSQ 96MA machine (Qiagen, 972824). Per cent methylation at each CpG locus was calculated using the Pyro Q CpG software (Biotage). The within assay coefficient of variation was less than 5% for all CpG loci that were measured and the limit of detection was 5% methylation.

![Sequences of the 5′ regions of (A) FADS2, (B) FADS1, (C) ELOVL5 and (D) ELOVL2 that were analysed by pyrosequencing.\
Individual CpG loci are indicated by their position relative to the transcription start site (bp) and are underlined. Sequences corresponding to CpG islands are indicated grey shading.](pone.0109896.g001){#pone-0109896-g001}

10.1371/journal.pone.0109896.t002

###### PCR primer sequences.

![](pone.0109896.t002){#pone-0109896-t002-2}

  Primer location(bp relative to TSS)    PCR primer sequences                                   
  ------------------------------------- ---------------------- -------------------------------- --------------------------------
                                                                            FADS1               
  --309                                         --309               GGAGGGTTAGAGTTTGGAGATT        CCCCCCATAAATCTTAAACAACTCACAA
  --392                                         --375               AGTGAATGGATTGAGGGGTTAG         CCCCCACCAAAACATCCACAACCTAA
  --504                                         --418               AGTGAATGGATTGAGGGGTTAG           ACCCCCACCAAAACATCCACA
  --586                                         --528            AGAGGTAAATAGGGTTATAAAAATTGTG    CCTCCAAAATTAAAAACTACTACCTACTTA
  --754                                                         AAGAGGTAAATAGGGTTATAAAAATTGTG     CCTCCAAAATTAAAAACTACTACCTACT
  --830                                                          AGGGTTTTTAGGAGTTTTTAGGTTAGAA    ACAATTTTTATAACCCTATTTACCTCTTT
  --905                                                          AAGAATAGTGTTTGGTATATAGTAAGTG    AACCTCTCCTAACCCTTAAATATTTCACCT
  --1037                                                         AAGAATAGTGTTTGGTATATAGTAAGTG      TCTCCTAACCCTTAAATATTTCACCT
                                                                            FADS2               
  --1661                                         1655              GTATGGTGGTTTTGAGGATTGTT       AAAATACTCCCTAATTCTACCTTTCAACTA
  --1337                                                          TTGTTGTGAAATTTAGATTGGGTAGG       CCTAAAAAAAATAAACCTAACTACAT
  --1278                                                          TTGTTGTGAAATTTAGATTGGGTAGG       CCTAAAAAAAATAAACCTAACTACAT
  --1156                                                          TTGTTGTGAAATTTAGATTGGGTAGG       CCTAAAAAAAATAAACCTAACTACAT
  --1119                                        --1101          ATTTGAGGGTTTTATAATTTTTTTAGTGAT     ACCCTAATCTCAATAAACTCAATCT
  --1071                                        --1056          ATTTGAGGGTTTTATAATTTTTTTAGTGAT    CCCTAATCTCAATAAACTCAATCTCTT
  --1013                                        --975           ATTTGAGGGTTTTATAATTTTTTTAGTGAT    CCTTACCCTAATCTCAATAAACTCAATC
  --914                                         --855            GGTAGTTTTTATTTGTTGGAGTTTGTAT      AAACCTCTACTCTACTTTCTTAATCT
  --817                                         --775            ATTGAGTTTATTGAGATTAGGGTAAGG      ACTTTAAACCCTCTAATCAAACAATCTT
  --718                                         --667             ATTGTTTGATTAGAGGGTTTAAAGTT         AAACTCCAATATCCCACATTAT
  --258                                         --244               AAGATTTTTTTGGGTTAATGGT            ATCCCTAACTTCCCAATACC
  --133                                          --84               AAGATTTTTTTGGGTTAATGGT           AAATCCCTAACTTCCCAATAC
  --64                                           --50               GGGGAGTTTTTATTGGAGGTAA           AATCCCTAACTTCCCAATACC
  --18                                                               TGGGGGTATTGGGAAGTTAG              CCCTCCCCCAACCTTCTC
                                                                           ELOVL 2              
  --237                                         --270              TTTGGGTAGAGGGTGGGTATTTT             CCTCTCCCACAAAAACCT
  --292                                         --350            AGATTGAGTAAATTTGTAGGAATAGAGT         AAACCCCAAAAATACCCACC
  --376                                                         AGGAGGTTATAGTTTTGTTTATAGTGAAGA        AAACCCCAAAAATACCCACC
  --429                                                         AGGAGGTTATAGTTTTGTTTATAGTGAAGA      TCCACCAAACCCCAAAAATACCC
  --481                                         --508           AGGAGGTTATAGTTTTGTTTATAGTGAAGA   CACATTAAAAAAAAATAACTCTATTCCTAC
                                                                           ELOVL 5              
  --6                                            --14             GGTTTATTAGGAAGAAAGGGGAAAA          AACCTAAACCCAAATTAACCCC
  --59                                          --100            GGGAGTTATGGTTATAATAGTTTTGAGT       ATTTTTTTCCCCTTTCTTCCTAAT
  --134                                         --185           AGGGAGTTATGGTTATAATAGTTTTGAGT     ACCCTAAACTCTAATTTTTTTACTACCA
  --231                                         --266           TTTTGTAAGGGAGTTATGGTTATAATAGT     ACCCTAAACTCTAATTTTTTTACTACC
  --269                                         --316             AGAGTAGAAATGGAGTTGATAGTGG       ACCCTAAACTCTAATTTTTTTACTACCA
  --633                                         --686               GGAGGTTGTAGTGAGTTGAGA        AACCTTCATTAACTTTATATCCTACTATT

TSS, transcription start site.

10.1371/journal.pone.0109896.t003

###### Pyrosequencing primers.
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  Starting location (bp relative to TSS)         Primer sequence
  ---------------------------------------- ---------------------------
                                                      FADS1
  --260                                     AGTTTTGGTTTTTTAGTTTATTTA
  --309                                          GATTGAGGGGTTAGG
  --392                                         GGTAGGGGTTGAGGTTT
  --504                                         AGGGTTTTTAGGTTGT
  --586                                     AGTTTTTTTTTAATTATTATTAAGT
  --754                                        AATATTTAAGGGTTAGGAG
  --830                                      CTAAAACATTTCTATTCTAACCT
  --905                                      AGTTTTGTAATTGGTAATTTTA
  --1037                                      GGAGAATTAAATGAGTTAAGG
                                                      FADS2
  --1661                                       TGGTTTTGAGGATTGTTAA
  --1337                                         AGATTGGGTAGGGTT
  --1278                                    GGTTTTTTATTTTTAAGTGAGATG
  --1156                                    GGGTTTTATAATTTTTTTAGTGAT
  --1119                                      AAAATAAACCTAACTACATCC
  --1071                                         CCTCAAACCCCAACT
  --1013                                      ATTATACAAACTCCAACAAAT
  --914                                      ATTATTGTTTAATGATGTGTTTG
  --817                                      CCTCTAATCAAACAATCTTAAAA
  --718                                      AGAGGGTTTAAAGTTTTTTAAT
  --258                                       GATTTTTTTGGGTTAATGGTA
  --133                                          GGGTAGAGGAGGTGT
  --64                                           CCCAATACCCCCAAA
  --18                                           GGGAAGTTAGGGATT
                                                     ELOVL2
  --237                                         GGGTATTTTTGGGGTT
  --292                                      GAAGTTTAATTGTAAGTAAGAT
  --376                                     TTATTTTTTTTTAATGTGTGTTTTA
  --429                                      AATAACTCTATTCCTACAAATT
  --481                                        AGAGATTTTTGTTTAGGG
  --6                                            [ELOVL 5]{.ul}
  --59                                       CCTAAACCCAAATTAACCCCTC
  --134                                      GTAAAAAAATTAGAGTTTAGGG
  --231                                     AGTATGATATAATTTATAGAGGAGA
  --269                                      ACTAAAAAAAATCCACTTCATC
  --633                                     AAATTAGAATTTTTAAGAAAAATAT

TSS, transcription start site.

Analysis of mRNA expression {#s2d}
---------------------------

mRNA was isolated from PBMCs using Tri Reagent (Sigma, T9429). Complementary DNA was prepared and amplified by real-time RT PCR using SYBR Green Jumpstart Ready Mix (Sigma, S4438) as described previously [@pone.0109896-Burdge3]. The level of mRNA expression was quantified using commercially prepared primer pairs for FADS1 Hs_FADS1_1\_SG QuantiTect primer assay, FADS2 (Hs_FADS2_1\_SG QuantiTect primer assay), ELOVL 2 (Hs_ELOVL2_1\_SG QuantiTect primer assay) (all from Qiagen). The assay conditions were as described by the manufacturer and were validated in house before use. ELVOL5 was quantified using bespoke primer sets (5′ to 3′ TATGAAGATTATCCGTGTC; 3′ to 5′ TGGCACCAAAATAAGAGT) (Eurofins Genomis, <http://eurofinsgenomics.eu>). Cycle parameters were 95°C for 2 minutes then 40 cycles of 95°C for 30 s, 55°C (cyclophilin, FADS1, FADS2, ELOVL2) or 60°C (ELOVL5) for 1 min and 72°C for 1 min. Samples were analysed in duplicate and the level of the individual transcripts was normalised to cyclophilin (Qiagen, Hs_PPIA_1\_SG QuantiTect primer assay) by the standard curve method [@pone.0109896-Cikos1].

Statistical analysis {#s2e}
--------------------

There are no previous data sets of methylation levels of the genes of interest on which to base calculations of sample size. Therefore, retrospective analysis of statistical power was carried out for exemplar levels of methylation of 95%, 47% and 17% in FADS2. For these levels of methylation, 7 subjects per group would provide a statistical power of 80% to detect a difference of 10% with a probability of P\<0.05. Male and female subjects were analyzed separately. The primary statistical analyses were as follows. Statistical comparisons of methylation level at baseline between male and female subjects were by Student's unpaired t test. Comparison of end of treatment values with baseline values was by Student's paired t test. The effect of treatment was determined by ANCOVA with supplement as a fixed factor and baseline methylation, age, BMI, proportion of lymphocytes and neutrophils as covariates with Bonferroni's *post hoc* correction. The relationship between the level of methylation at individual CpG loci and that of the mRNA expression of the corresponding transcript was by Pearson's correlation analysis.

Results {#s3}
=======

Subjects {#s3a}
--------

There were no significant differences by one-way ANOVA in the characteristics of the subjects at baseline between the dietary supplementation groups in the Study 1 cohort ([Table 1](#pone-0109896-t001){ref-type="table"}). However, the subjects in the Study 2 cohort were significantly younger (P\<0.001) and had a lower BMI (P\<0.001) than the subjects in the Study 1 cohort ([Table 1](#pone-0109896-t001){ref-type="table"}). There were no significant differences in subject characteristics between males and females in either cohort.

Methylation at baseline in the Study 1 cohort {#s3b}
---------------------------------------------

Since the limit of detection was 5%, CpG loci that exhibited methylation of 5% or less were regarded as essentially unmethylated. This is consistent with previous reports [@pone.0109896-Tsiatis1]. The level of methylation of FADS2, FADS1 and ELOVL5 tended to be related inversely to distance from the transcription start site (TSS) ([Figure 2](#pone-0109896-g002){ref-type="fig"} A--C). While this transition was gradual for FADS2, there appeared to be a sharp demarcation between a highly methylated (\>70%) region distal to the TSS and the proximal region which was essentially unmethylated region in FADS1 and ELOVL5 which is consistent with the presence of CpG islands within the proximal promoters of FADS1 and ELOVL5 ([Figure 1](#pone-0109896-g001){ref-type="fig"}). Methylation of individual CpG loci in the 5′ regulatory region of ELOVL2 appeared to be essentially uniform with methylation levels between approximately 10% to 20%, with the exception of a CpG located at −429 bp from the TSS (CpG −429) which had a markedly greater level of methylation, approximately 80%, compared to the other CpG loci that were measured in this gene ([Figure 2D](#pone-0109896-g002){ref-type="fig"}).

![Values are mean ± SEM methylation of individual CpG loci at baseline in the 5′ regulatory regions of (A) FADS2, (B) FADS1, (C) ELOVL5 and (D) ELOVL2 in PBMCs from male (open bars) and female (closed bars) subjects in the Study 1 cohort.\
Numbers of subjects are listed in [Table 1](#pone-0109896-t001){ref-type="table"}. Locations of individual CpG dinucleotides are relative to the transcription start site (TSS). Dotted horizontal line indicates the analytical limit of the assay.](pone.0109896.g002){#pone-0109896-g002}

Effect of dietary supplementation with n-3 LCPUFA or OO on the methylation of individual CpG loci in the Study 1 cohort {#s3c}
-----------------------------------------------------------------------------------------------------------------------

Both OO and n-3 LCPUFA induced significant changes compared to baseline in the level of methylation of individual CpG loci in specific genes involved in PUFA metabolism in PBMCs in the Study 1 cohort that were contingent on sex. In males, n-3 LCPUFA increased methylation at CpG −806 (12.5%) in FADS2 compared to baseline, but decreased methylation at CpG−775 (11.8%) ([Figure 3A](#pone-0109896-g003){ref-type="fig"}). Supplementation with OO increased the level of methylation compared to baseline at both of these loci by 13% and 24.0%, respectively ([Figure 3A](#pone-0109896-g003){ref-type="fig"}). In females, n-3 LCPUFA supplementation induced increased methylation of FADS2 at CpGs −1071 (8.0%), −975 (6.2%), −871 (4.6%) and at CpG−775 (8.9%) compared to baseline ([Figure 3B](#pone-0109896-g003){ref-type="fig"}). Supplementation with OO increased methylation at CpGs −1119 (6.3%), −1101 (14.6%), −871 (13.1%), −869 (16.5%), −855 (13.3%), −817 (17.5%), −806 (13.9%) and CpG −775 (8.9%) compared to baseline ([Figure 3B](#pone-0109896-g003){ref-type="fig"}).

![Values are mean ± SEM difference in methylation from baseline of individual CpG loci in the 5′ regulatory regions of (A, B) FADS2, (C, D) FADS1, (E, F) ELOVL5 and (G, H) ELOVL2 in PBMCs from male (A, C, E, G) and female (B, D, F, H) subjects in the Study 1 cohort who received n-3 LCPUFA (open bars) or OO (closed bars) supplements.\
Numbers of subjects are listed in [Table 1](#pone-0109896-t001){ref-type="table"}. Locations of individual CpG dinucleotides are relative to the transcription start site (TSS). \*Means that were significantly different by Student's paired t test between baseline and end of intervention samples are indicated by ^a^P\<0.05, ^b^P\<0.01, ^c^P\<0.001, ^d^P\<0.0001.](pone.0109896.g003){#pone-0109896-g003}

In males, supplementation with n-3 LCPUFA increased the level of methylation of CpG −686 (10.1%) compared to baseline in ELOVL5, but did not alter significantly the level of methylation of the other CpGs that were measured ([Figure 2E](#pone-0109896-g002){ref-type="fig"}). There was no significant effect of supplementation with OO on the methylation of CpG loci in ELOVL5 ([Figure 2E](#pone-0109896-g002){ref-type="fig"}). In females, n-3 LCPUFA supplementation increased the level of methylation of CpG −686 (3.1%) and CpG −269 (2.1%) in ELOVL5 compared to baseline ([Figure 3F](#pone-0109896-g003){ref-type="fig"}). Supplementation with OO decreased methylation of CpG −686 (3.1%), but increased methylation of CpG −269 (7.6%) and CpG −259 (4.6%) compared to baseline ([Figure 2F](#pone-0109896-g002){ref-type="fig"}). There was no significant effect of supplementation with either n-3 LCPUFA or OO on the level of methylation of any of the CpGs measured in FADS1 or in ELOVL2 in males or females ([Figure 3C, D, G, H](#pone-0109896-g003){ref-type="fig"}).

In males, the type of oil used in the dietary supplement induced differential methylation of CpG −775 (22%) in FADS2 ([Table 4](#pone-0109896-t004){ref-type="table"}) and of CpG −686 (11%) in ELOVL5 ([Table 5](#pone-0109896-t005){ref-type="table"}). In females, supplementation induced differential methylation of CpGs −1071 (8.5%), −975 (4.1%), −871 (8.2%), −869 (10.7%), −855 (10.0%), −817 (22.1%) and −775 (7.4%) in FADS2 ([Table 4](#pone-0109896-t004){ref-type="table"}). The type of dietary oil supplement induced differential methylation at CpG −686 in males (11%) and in females (6.5%) in ELOVL5 ([Table 5](#pone-0109896-t005){ref-type="table"}). There were no significant differences between the effects of the dietary supplements on the methylation of other CpG loci in FADS2 or ELOVL5, nor in the level of methylation of any other CpG loci measured in FADS1 or ELOVL 2 in males or females ([Tables 4](#pone-0109896-t004){ref-type="table"} and [5](#pone-0109896-t005){ref-type="table"}).

10.1371/journal.pone.0109896.t004

###### Effect of supplementation with n-3 LCPUFA or olive oil on DNA methylation of FADS2 and FADS1 in the Study 1 cohort.

![](pone.0109896.t004){#pone-0109896-t004-4}

            Methylation of individual CpG loci (%)                                                                           
  -------- ---------------------------------------- ----------- ---------- --------------- ----------- ---------- ---------- --------------
                            FADS2                                                                                            
  --1661                   95.0±1.6                  93.6±1.2    95.1±0.5     93.4±0.6      92.4±4.4    94.0±1.5   93.7±1.5     93.7±1.2
  --1665                   88.7±1.1                  88.7±1.8    88.8±0.4     88.7±0.5      84.6±2.2    89.5±1.3   84.5±2.3     89.6±2.2
  --1337                   83.7±3.5                  81.6±3.2    82.8±0.8    81.3±0.8\*     79.6±3.7    7.77±5.2   79.7±2.1     77.2±2.2
  --1156                   61.9±8.8                  61.3±5.3    61.9±3.0     61.3±2.6      61.7±7.0    58.4±5.8   61.1±2.4     59.8±2.3
  --1119                   22.8±5.2                  22.8±5.8    22.7±1.9     21.9±2.1      25.8±6.3    28.5±7.8   25.8±2.1     29.9±2.3
  --1112                   41.7±5.2                  34.0±5.0    41.7±2.4     33.9±2.0      31.3±8.9    40.9±7.3   39.2±3.4     41.9±3.8
  --1101                   34.9±8.1                  35.9±8.0    34.6±2.3     36.3±2.5      35.8±4.7    41.2±2.9   37.5±3.4     40.9±7.6
  --1071                   44.6±3.2                  45.0±4.4    44.7±1.9     44.8±2.6      53.4±7.7    43.4±5.2   52.6±1.3    44.1±1.3\*
  --1067                   46.7±4.7                  49.7±8.1    46.5±2.0     49.6±2.7      47.2±6.3    46.3±7.3   48.3±4.0     47.6±3.6
  --1056                   36.9±7.3                  39.0±8.4    40.14.4      39.1±3.5      35.7±5.9    37.4±7.1   35.6±4.2     37.1±3.4
  --1013                   46.1±3.0                  39.4±8.8    46.2±3.0     39.4±2.6      44.8±4.5    43.7±4.7   44.9±1.8     44.1±1.8
  --975                    52.7±5.1                  48.3±10.1   52.3±2.4     50.5±2.6      60.8±8.3    48.1±4.7   57.3±1.4    53.2±1.5\*
  --914                    19.6±6.3                  20.8±5.2    19.8±1.3     20.6±1.6      21.7±5.8    18.3±5.1   21.9±2.8     19.8±2.9
  --871                    25.4±5.8                  30.3±4.4    27.9±1.6     29.3±1.7      30.6±7.2    33.1±8.3   27.2±3.0    35.4±2.8\*
  --869                    21.9±5.4                  24.0±6.4    22.6±2.7     23.6±3.6      27.4±5.9    33.1±4.0   23.7±1.5   34.4±1.9\*\*
  --855                    27.6±4.9                  22.1±9.8    29.1±2.8     20.8±3.9      29.2±4.7    35.6±4.4   28.7±1.0   38.7±1.4\*\*
  --817                    24.1±5.4                  21.2±4.9    23.7±4.3     22.4±3.6      17.7±11.8   31.5±5.6   14.8±4.9   36.9±5.7\*\*
  --806                    50.0±2.3                  50.8±2.0    50.0±0.9     50.9±1.0      38.0±9.2    37.7±5.7   37.8±1.5   51.6±4.0\*\*
  --775                    23.6±7.8                  45.8±4.3    23.6±7.7   45.8±4.36\*\*   47.0±3.5    33.5±2.1   44.8±4.3   37.4±2.2\*\*
  --64                     1.6±0.9                    2.1±1.2    1.6±0.3       2.1±0.4       1.7±0.9    1.9±0.3    1.6±0.3      1.9±0.2
  --50                     3.8±0.9                    5.7±3.4    3.7±0.6       5.7±0.8       3.6±0.5    3.5±0.9    3.6±0.3      3.5±0.3
  --18                     4.1±0.7                    4.2±0.5    4.1±0.3       4.1±0.4       4.1±0.7    4.4±0.9    4.2±0.4      4.3±0.4
                            FADS1                                                                                            
  --1037                   76.3±4.3                  78.2±4.3    77.9±2.8     76.6±2.2      74.8±2.0    75.4±5.2   72.7±2.0     69.7±1.9
  --830                    83.3±2.8                  82.9±1.9    83.4±0.7     82.7±0.8      84.1±2.5    85.2±3.8   85.2±1.2     84.1±1.9
  --586                    26.5±5.7                  28.1±5.1    27.2±2.0     27.8±1.9      23.0±5.1    23.3±3.6   23.7±1.6     22.7±2.3
  --528                    1.9±1.0                    3.7±1.8    2.9±0.7       3.7±0.6       3.0±1.0    2.6±0.8    2.6±0.3      2.6±0.4
  --512                    1.0±1.2                    2.2±1.7    1.8±0.6       1.8±0.3       2.8±0.5    2.8±0.7    2.9±0.2      2.7±0.3
  --507                    2.9±1.6                    3.6±1.1    3.0±0.6       3.7±0.6       3.3±0.7    2.2±1.5    3.4±0.3      2.6±1.0
  --504                    2.0±2.1                    2.6±1.2    2.2±0.5       2.6±0.5       3.0±0.9    2.46±1.4   3.1±0.3      2.8±.0.5

Values are mean or adjusted (Adj) mean ±SEM methylation of individual CpG loci at the end of the dietary intervention period in individuals who received either the n-3 LCPUFA or OO supplements. Numbers of subjects are indicated in [Table 1](#pone-0109896-t001){ref-type="table"}. Comparisons between the level of methylation of individual CpG loci between supplementation groups at the end of the intervention were by ANCOVA. Means were adjusted for the level of methylation at baseline, age, BMI, and proportion of lymphocytes and neutrophils in blood, with Bonferroni's *post hoc* correction. Adjusted means that were differed significantly are indicated by \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001, \*\*\*\*P\<0.0001. Individual CpG dinucleotides are indicated by their position relative to the transcription start site (bp).

10.1371/journal.pone.0109896.t005

###### Effect of supplementation with n-3 LCPUFA or olive oil on DNA methylation of ELOVL5 and 2 in the Study 1 cohort.

![](pone.0109896.t005){#pone-0109896-t005-5}

           Methylation of individual CpG loci (%)                                                                      
  ------- ---------------------------------------- ---------- ---------- ------------ ---------- ---------- ---------- --------------
                          ELOVL 5                                                                                      
  --686                   83.4±3.4                  76.4±2.5   85.0±1.1   74.0±2.8\*   83.1±3.1   75.2±4.7   82.4±1.2   75.9±1.1\*\*
  --633                   77.2±8.9                  74.6±3.2   77.4±3.2    78.2±5.5    72.4±2.3   72.1±4.2   72.5±2.3     72.1±4.2
  --269                   5.6±1.2                   5.1±1.8    5.8±0.6     4.3±0.6     9.8±1.2    4.8±1.5    4.7±0.7      5.9±1.3
  --266                   7.6±1.8                   7.5±2.2    8.9±5.4     8.1±5.1     7.1±1.7    6.8±2.7    5.6±3.1      7.3±2.9
  --259                   5.3±0.8                   5.1±0.7    5.3±0.3     4.9±0.3     4.5±1.9    6.6±0.8    5.1±0.9      8.2±1.3
  --231                   2.0±0.5                   2.1±0.6    3.5±1.4     2.3±0.2     2.9±0.8    2.6±0.5    2.5±0.3      3.0±0.4
  --185                   9.8±2.6                   8.2±1.1    8.0±0.5     9.4±0.7     8.1±1.0    9.9±2.1    9.3±0.8      8.1±0.9
  --180                   13.3±3.3                  12.4±0.7   13.5±1.0    12.5±1.5    14.5±2.4   12.7±1.2   14.1±0.8     12.7±0.9
  --153                   2.8±1.5                   3.5±1.0    2.5±0.4     3.4±0.6     3.9±0.9    3.3±1.5    3.8±0.4      2.9±0.5
  --134                   6.6±2.0                   6.3±1.9    6.1±0.7     5.9±1.1     7.7±2.8    6.9±1.3    7.9±1.0      6.6±1.3
  --14                    3.6±0.9                   3.7±2.0    3.6±0.4     3.8±0.5     3.7±1.5    4.6±1.2    3.7±0.5      4.6±0.5
  --6                     1.5±0.6                   2.1±0.5    1.5±0.5     11.9±6.2    1.8±0.3    1.9±0.4    1.8±0.1      2.4±0.3
                          ELOVL 2                                                                                      
  --508                   18.4±3.2                  16.8±7.3   19.4±2.3    16.8±2.1    17.3±6.4   20.6±5.5   15.7±2.2     21.9±2.3
  --501                   24.0±5.7                  22.3±8.5   23.8±2.6    22.5±2.6    24.8±6.4   22.1±4.3   24.9±2.6     22.0±2.6
  --491                   21.4±4.5                  22.4±5.3   21.8±2.4    22.0±2.0    24.1±6.2   23.8±6.2   23.8±2.3     24.12.1
  --481                   16.3±4.3                  15.1±3.1   16.2±1.3    15.1±1.3    14.8±3.6   16.2±4.2   15.0±1.5     16.5±1.3
  --429                   77.5±6.9                  74.4±4.2   78.0±2.0    75.1±2.4    76.4±4.1   71.1±4.9   76.5±2.2     71.9±2.5
  --350                   13.6±4.8                  15.6±3.5   14.1±1.5    15.8±1.7    16.9±3.6   16.8±3.4   16.3±1.6     15.1±1.8
  --344                   20.1±5.0                  22.1±3.7   20.0±1.2    21.9±1.4    19.3±2.7   21.5±2.3   18.8±1.2     21.1±1.3
  --335                   8.6±1.3                   7.9±1.7    8.1±0.4     8.7±0.5     8.6±2.7    9.7±1.4    8.8±0.9      9.5±0.9
  --319                   14.1±1.9                  12.6±4.9   14.1±1.1    13.1±1.4    12.1±6.7   14.9±2.6   10.8±1.7     14.7±1.7
  --304                   8.9±2.9                   11.0±1.1   8.9±0.8     11.8±1.4    10.9±2.5   11.7±1.7   11.4±0.8     11.8±0.9
  --292                   9.9±4.3                   9.8±1.6    9.8±0.8     11.2±0.8    10.2±1.5   10.3±2.7   10.0±0.8     10.9±0.9

Values are mean or adjusted (Adj) mean±SEM methylation of individual CpG loci at the end of the dietary intervention period in individuals who received either the n-3 LCPUFA or OO supplements. Numbers of subjects are indicated in [Table 1](#pone-0109896-t001){ref-type="table"}. Comparisons between the level of methylation of individual CpG loci between supplementation groups at the end of the intervention were by ANCOVA. Means were adjusted for the level of methylation at baseline, age, BMI, and proportion of lymphocytes and neutrophils in blood, with Bonferroni's *post hoc* correction. Adjusted means that were differed significantly are indicated by \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001, \*\*\*\*P\<0.0001. Individual CpG dinucleotides are indicated by their position relative to the transcription start site (bp).

Effect of dietary supplementation with n-3 LCPUFA on the methylation of individual CpG loci in the Study 2 cohort {#s3d}
-----------------------------------------------------------------------------------------------------------------

We investigated whether the changes in methylation induced by supplementation with n-3 LCPUFA in the Study 1 cohort could be replicated in a second cohort of health individuals. For FADS2, n-3 LCPUFA supplementation in the Study 2 cohort also induced an increase in methylation at CpGs −803 and −775 in males and in CpGs −1071, −975 and −775 in females ([Figure 4A](#pone-0109896-g004){ref-type="fig"}) to those induced in the UWA cohort ([Figure 2](#pone-0109896-g002){ref-type="fig"} A, E). However, increased methylation at CpG −871 in females in the UWA cohort was not replicated in the Study 2 cohort ([Figure 4A](#pone-0109896-g004){ref-type="fig"}). For ELOVL5, the level of methylation of CpG −686 was increased compared to baseline in both the Study 1 and Study 2 cohorts ([Figure 4B](#pone-0109896-g004){ref-type="fig"}). However, the level of methylation of CpG −269, which was increased compared to baseline in females who received the n-3 LCPUFA supplement in the Study 1 cohort, was unchanged in females in the Study 2 cohort. CpGs in FADS2 or ELOVL5 that were measured in the same amplicons as those that showed altered methylation, but which did not exhibit a change in methylation following n-3 LCPUFA supplementation in the Study 1 cohort, also did not show altered methylation in the Study 2 cohort ([Figure 4](#pone-0109896-g004){ref-type="fig"}).

![Values are mean ± SEM difference in the methylation of individual CpG loci from baseline in the 5′ regulatory regions of (A) FADS2 and (B) ELOVL5 in PBMCs from male (open bars) and female (closed bars) in the Study 1 cohort who consumed a n-3 LCPUFA supplement.\
Numbers of subjects are listed in [Table 1](#pone-0109896-t001){ref-type="table"}. Locations of individual CpG dinucleotides are relative to the transcription start site (TSS). \*Means that were significantly different (P\<0.05) by Student's paired t test between baseline and end of intervention samples.](pone.0109896.g004){#pone-0109896-g004}

The relationship between the methylation of individual CpG loci and the mRNA level of the corresponding transcripts {#s3e}
-------------------------------------------------------------------------------------------------------------------

The level of methylation of specific CpG loci in FADS2 and ELOVL5, but not FADS1 nor ELOVL2, in the Study 1 cohort were associated significantly the level of the mRNA transcript in samples collected at the end of the study irrespective of subject sex or dietary supplement. There were no significant differences in FADS1 or ELOVL2 mRNA expression between baseline and end of study samples ([Figure 5](#pone-0109896-g005){ref-type="fig"} A, C). However, the mRNA expression of FADS2 was reduced significantly in all dietary groups, while ELOVL5 expression was reduced in females who received the OO supplement and in males who received with the OO or n-3 LCPUFA supplement at the end of the study compared to baseline ([Figure 5](#pone-0109896-g005){ref-type="fig"} B, D). The CpGs at −119, −871, −869, −806 and −775, which showed altered methylation in response to dietary supplementation, were associated negatively with the level of the FADS2 transcript ([Table 6](#pone-0109896-t006){ref-type="table"}). The CpGs −686 and −259 in ELOVL5, which showed altered methylation in response to dietary supplementation, were associated negatively with the level of the ELOVL5 transcript ([Table 6](#pone-0109896-t006){ref-type="table"}). These associations are illustrated for FADS2 CpG −775 and ELOVL 5 CpG −686 in [Figure 6](#pone-0109896-g006){ref-type="fig"}.

![Change in relative mRNA expression of (A) FADS1, (B) FADS2, (C) ELOVL2 and (D) ELOVL5 in peripheral blood mononuclear cells from Study 1.\
\*Means at the end of the end of the study that were significantly different (P\<0.05) compared to baseline assessed by Student's paired t test. Combined data refers to the overall change in mRNA expression irrespective of sex or supplement (these data were used to test the statistical association with the methylation status of the respective genes).](pone.0109896.g005){#pone-0109896-g005}

![Change in relative mRNA expression compared to change in the methylation status of (A) FADS2 CpG −775 and (B) ELOVL5 CpG −686 irrespective of subject sex or supplementation group in peripheral blood mononuclear cells from Study 1.\
The corresponding correlation efficients are shown in [Table 6](#pone-0109896-t006){ref-type="table"}.](pone.0109896.g006){#pone-0109896-g006}

10.1371/journal.pone.0109896.t006

###### The relationship between the methylation status of individual CpG loci at the end of the intervention study and expression of the corresponding mRNA in the Study 1 cohort.

![](pone.0109896.t006){#pone-0109896-t006-6}

  Pearson's correlations                                                                                   
  ------------------------ -------- ------- -------- -------- -- ------- -------- ------- ------- -------- --
  --1661                    --0.05           --1037   --0.06      --686   --0.32   0.009   --508    0.3    
  --1665                    --0.06           --830    --0.5       --633    0.04            --501   --0.44  
  --1337                     0.03            --586     0.09       --269   --0.11           --491    0.20   
  --1156                     0.21            --528    --0.1       --266   --0.15           --481    0.1    
  --1119                    --0.57   0.009   --512    --0.24      --259   --0.18   0.038   --429   --0.25  
  --1112                     0.15            --507     0.05       --231   --0.22           --350   --0.08  
  --1101                     0.18            --504    --0.05      --185   --0.1            --344    0.05   
  --1071                    --0.12                                --180   --0.37           --335    0.24   
  --1067                     0.11                                 --153   --0.1            --319    0.08   
  --1056                     0.17                                 --134    0.0             --304    0.29   
  --1013                     0.14                                 --14    --0.07           --292   --0.12  
  --975                      0.11                                  --6    --0.08                           
  --914                      0.01                                                                          
  --871                     --0.17   0.047                                                                 
  --869                     --0.31   0.017                                                                 
  --855                      0.08                                                                          
  --817                      0.12                                                                          
  --806                     --0.52   0.007                                                                 
  --775                     --0.21   0.043                                                                 
  --64                      --0.02                                                                         
  --50                      --0.06                                                                         
  --18                       0.02                                                                          

Values are Person's correlation coefficients and probabilities for the relationship between methylation of individual CpG loci and the level of the corresponding mRNA transcript at the end of the intervention study. Numbers of subjects are indicated in [Table 1](#pone-0109896-t001){ref-type="table"}.

Discussion {#s4}
==========

The findings of this study show for the first time that modest dietary supplementation with either n-9 monounsaturated fatty acids or n-3 LCPUFA induces altered DNA methylation in specific genes involved in LCPUFA metabolism in leukocytes from adults that differed between the type of supplement and between sexes.

The methylation profile of CpGs within the 5′ regulatory region of the four key genes involved in LCPUFA biosynthesis has not been reported previously in humans. FADS2 was characterised by a gradual decline in the level of methylation of individual CpG loci 90% to 20% with decreasing distance from the transcription start site. Previous reports in rodents have shown that the level of methylation of the Fads2 promoter in mice was less than 10% [@pone.0109896-Niculescu1], [@pone.0109896-Devlin1], while in rats the level of methylation was between 30% and 90%, increasing with distance from the transcription start site [@pone.0109896-Hoile1], [@pone.0109896-Kelsall1]. This implies that the epigenetic regulation of this gene may be more similar in humans to rats, than to mice, which may have implications for understanding the epigenetic regulation of FADS2 in these species. However, since FADS2 appears to have multiple TSS ([http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000134824;r=11∶61560452--61634826](http://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000134824;r=11:61560452--61634826)), detailed promoter mapping in the different species would be necessary to establish differential species-specific regulation of this gene. The level of methylation of some CpG loci in the 5′ regulatory region of FADS2 has been reported previously in HepG2 cells [@pone.0109896-Sibbons1]. Despite prolonged passage of this hepatocellular carcinoma cell line in culture, the methylation levels of the CpG loci that were measured were comparable to those reported here, with the exception of CpG −1661, which had approximately 30% lower methylation in HepG2 cells [@pone.0109896-Sibbons1]. Whether this difference in methylation reflects an effect of prolonged adaptation to *in vitro* culture or differences in cell type between leukocytes and hepatocellular carcinoma cells cannot be determined from these findings. However, together these observations suggest that the epigenetic regulation of the FADS2 gene may be similar in the two distinct cell types and that HepG2 cells may be a suitable model of the epigenetic regulation of FADS2 in humans.

FADS1 and ELOVL5 showed a marked demarcation between a highly methylated region distal to the transcription start site and an essentially unmethylated proximal region. ELOVL2 showed a similar level of methylation, about 20% across the region that was measured with the exception of CpG −429 that showed markedly higher methylation. However, the role of this CpG locus in the regulation of ELOVL2 and the effect of differential methylation of this site on the transcription of the gene is not known.

There is substantial evidence that women have higher DHA status [@pone.0109896-Lohner1] and capacity for DHA synthesis [@pone.0109896-Burdge4], [@pone.0109896-Burdge5] than men. This sex difference has also been shown in rodents to be accompanied by differential mRNA expression of Fads2 and Fads1 in the liver [@pone.0109896-Burdge6], [@pone.0109896-Childs1]. In the present study, we found no differences between men and women in the methylation status of individual CpG loci in any of the gene regions that were investigated. This suggests that differential methylation of FADS1 or 2, or of ELOVL 2 or 5 may not contribute significantly to the sex difference in DHA status. Previous studies have shown that supplementation of pregnant rodents with different types and amounts of dietary fats induced hypermethylation of specific CpG loci in the Fads2, but not Fads1, promoter in the liver and aortae of the offspring [@pone.0109896-Hoile1], [@pone.0109896-Kelsall1]. The nature of such changes differed according to the type and amount of fat in the maternal diet. Similarly, feeding adult rats a diet enriched in fish oil induced hypermethylation of specific CpG loci in the Fads2 promoter which was reversed by withdrawal of the high n-3 LCPUFA diet [@pone.0109896-Hoile1]. Feeding adult male mice a high fat diet induced hypermethylation of specific CpG loci in stearoyl-CoA desaturase [@pone.0109896-Schwenk1]. Treatment of cells in culture with EPA has also been shown to induce altered methylation of sCCAAT/enhancer binding protein-β [@pone.0109896-Ceccarelli1]. To our knowledge there have been relatively few studies of the effect of dietary fat on DNA methylation in humans. Consuming a high fat diet for 5 days induced altered methylation of 7,909 CpG loci in 658 genes in skeletal muscle from young men [@pone.0109896-Jacobsen1]. Feeding 400 mg DHA per day to pregnant women from mid gestation to term induced a small increase (about 1%) in the methylation status of LINE-1 sequences in leukocytes from umbilical cord blood [@pone.0109896-Lee1]. However, the nature of the latter study design may limit the interpretation of these findings [@pone.0109896-Burdge7]. The current findings show that consuming supplements enriched in n-9 monounsaturated fatty acids or n-3 LCPUFA induces differential changes in the methylation of individual CpG loci in two out of the four genes that were investigated. Such differential effects are consistent with previous findings in rodents [@pone.0109896-Kelsall1]. Furthermore, the pattern of induced changes in DNA methylation differed between men and women such that in terms of the number of CpG loci that were affected, the effect of the dietary supplements was greater in women than in men in both FADS2 and ELOVL5.

The effects of supplementation with n-3 LCPUFA that were observed in the patients with chronic kidney disease were fairly well replicated in the cohort of healthy individuals in terms of the number and location of the CpGs that were changed in both FADS2 and ELOVL5, and the direction of the effect on these genes. There were two exceptions, CpG −871 in FADS2 and CpG −269 in ELOVL5 showed increased methylation (approximately 5%) in women in the Study 1 cohort who consumed the n-3 LCPUFA supplement, but were unchanged in the Study 2 cohort. However, overall these findings suggest that effect of supplementation with n-3 LCPUFA on DNA methylation of FADS2 and ELOVL5 was not affected significantly by differences in the fatty acid composition of the n-3 LCPUFA preparations, or the age, BMI, health status or geographical location of the subjects. Since the changes induced in the methylation of FADS2 and ELOVL5 were similar after either 8 or 12 weeks supplementation, these findings also suggest that the effects of increased intakes of n-3 LCPUFA had reached a maximum response by 2 months. CpGs in FADS2 and ELOVL that were proximal to those that showed altered methylation but were unaffected by the dietary supplement in the Study 1 cohort, were also unaffected in the Study 2 cohort. This confirms the specificity of the effects of the different fatty acid supplements.

The methylation status of specific CpG loci in Fads2 has been shown previously in rats to directly influence the level of transcription [@pone.0109896-Kelsall1]. We investigated whether the level of methylation of individual CpG loci in the four genes of interest was associated with the level of the corresponding transcripts. We found that the methylation status of four CpG loci in FADS2 and one CpG loci in ELOV5, which showed induced changes in methylation following dietary supplementation, were negatively associated with the level of the FADS2 and ELOVL5 transcripts, respectively. Although this does not provide a direct functional assessment of the effect of altered methylation at these loci on the level of transcription, such associations are consistent with increasing DNA methylation inducing a lower level of transcription. Increased total dietary fat intake [@pone.0109896-Cho1], [@pone.0109896-Cho2], or supplementation with olive oil [@pone.0109896-Haban1] or n-3 LCPUFA [@pone.0109896-Garg1] has been shown to decrease the conversion of 18 carbon essential fatty acids to their longer chain metabolites. The present findings suggest that increased intakes of n-3 LCPUFA or olive oil may reduce PUFA biosynthesis via changes in the epigenetic regulation of FADS2 and ELOVL5 that affect gene transcription, possibly in addition to any effect of product inhibition. Since olive oil is not a pure preparation of fatty acids, it cannot be assumed that the changes in DNA methylation were due to the lipid content of the oil since other biologically active compounds are present such as polyphenols [@pone.0109896-Visioli1]. Because D6d is the rate-limiting enzyme in PUFA biosynthesis, lower transcription of FADS2 would tend to down-regulate the activity of the whole pathway. However, lower transcription of ELOVL5 may reduce conversion of dihomo-γ-linolenic acid to archidonic acid and EPA to DPAn-3. If so, one possible consequence could be to increase the synthesis of substrates for the synthesis of prostaglandin (PG) E~1~ and PGE3, relative to PGE~2~.

The nature of this study design has some limitations. Although retrospective analysis suggested that the study was adequately powered to detect differences of 10%, changes in methylation of less than10% need to be considered cautiously. Replication of the study in a larger prospective cohort of healthy individuals, preferably with a crossover rather than parallel design, would be desirable to substantiate the current findings. It would also be desirable to test the dietary supplements at more than one dose. Because cell differentiation involves differential changes in the methylation of individual genes, it is possible that variations in cell populations may have contributed to the variation in the level of methylation of individual CpG loci, although differences in the proportions of individual cell populations were taken into account in the analysis of the samples from the Study 1 cohort. Furthermore, the similarities in the findings from the Study 2 cohort, which were based on DNA isolated from whole blood without correction for leukocyte sub-types, to those from the Study 1 cohort supports the suggestion that variation in cell populations does not significantly affect the methylation of these genes. Finally, although there were significant associations between the methylation status of individual CpG loci and the level of the corresponding mRNA transcripts, the effect of variation in DNA methylation of these genes on their transcription and on PUFA biosynthesis remain to be demonstrated directly.

Overall, the findings of this study show that dietary supplementation of adult humans with modest amounts of n-3LCPUFA or olive oil can induce selective changes in the methylation status of individual CpG loci in specific genes, which is contingent on the sex of the subject and the nature of the supplement. Such findings may have implications for understanding the mechanisms the underlie the health benefits associated with higher consumption of fish oil [@pone.0109896-Calder1], [@pone.0109896-Sijben1] or olive oil [@pone.0109896-Bester1]. Furthermore, altered DNA methylation has been implicated as a causal process in a number of non-communicable diseases [@pone.0109896-Burdge1], [@pone.0109896-Burdge2]. One challenge in the design of therapeutic strategies to ameliorate or reverse altered patterns of DNA methylation in disease states is targeting the intervention to specific CpG loci [@pone.0109896-Burdge8]. One possible implication of the current findings is that supplementation with specific fatty acids or combinations of fatty acids may provide a means of delivering health benefits by inducing selective modification of the methylation status of specific CpG loci.
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